Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 1:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sclerosis Clear all
Completed Phase 3 Interventional Results available

An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab

NCT00930553
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
alemtuzumab
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
1,314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
69
States / cities
Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 9, 2026, 1:51 AM EDT
Completed No phase listed Observational

Assessment of Patients With Multiple Sclerosis (MS)

NCT00001156
View directory record Official record
Conditions
Herpesviridae Infection, HTLV-I Infection, Multiple Sclerosis, Tropical Spastic Paraparesis, Vasculitis
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 75 Years
Enrollment
1,388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1976 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 9, 2026, 1:51 AM EDT
Terminated Phase 2 Interventional Results available

An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)

NCT05626751
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
Interventions
HZN-825
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 9, 2026, 1:51 AM EDT
Recruiting Phase 1Phase 2 Interventional

Intestinal Microbiome Transplant in ALS

NCT07017946
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis ALS
Interventions
MTP-101C
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 9, 2026, 1:51 AM EDT
Completed No phase listed Observational Results available

Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study

NCT04754542
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
55 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Aurora, Colorado • Kansas City, Kansas • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Sep 9, 2026, 1:51 AM EDT
Terminated Phase 1Phase 2 Interventional

Cannabis for Spasticity in Multiple Sclerosis

NCT00260741
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Smoked Cannabis
Drug
Lead sponsor
Center for Medicinal Cannabis Research
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2007 · Synced Sep 9, 2026, 1:51 AM EDT
Not yet recruiting Not applicable Interventional

Comparison of Gait Metrics in Patients With Stroke, Traumatic Brain Injury, and Multiple Sclerosis

NCT07492602
View directory record Official record
Conditions
Stroke, Traumatic Brain Injury, Multiple Sclerosis
Interventions
Functional Electrical Stimulation, Normal care
Device
Lead sponsor
Casa Colina Hospital and Centers for Healthcare
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 9, 2026, 1:51 AM EDT
Completed No phase listed Observational

A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients

NCT06897657
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Sep 9, 2026, 1:51 AM EDT
Completed Not applicable Interventional

Development of a Talk Therapy Protocol to Help Patients Make Treatment Decisions in MS

NCT02010554
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Brief Education, Motivational Interviewing-Cognitive Behavioral Therapy
Behavioral
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Kansas City, Missouri • West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 1, 2015 · Synced Sep 9, 2026, 1:51 AM EDT
Withdrawn Phase 4 Interventional

Assessing the Cognitive Benefits of Ozanimod and Their Brain-Biomarkers in MS

NCT06334094
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ozanimod
Drug
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 9, 2026, 1:51 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Linking Cognitive Functioning to Multimodal Imaging in Multiple Sclerosis (MS)

NCT03723356
View directory record Official record
Conditions
Multiple Sclerosis, Cognition Disorders
Interventions
Siemens Biograph mMR (molecular MR), fMRI, Diffusion Spectrum Imaging (DSI)
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 45 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 9, 2026, 1:51 AM EDT
Not listed Phase 4 Interventional

A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab

NCT04048577
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Dosing Interruption of Natalizumab
Drug
Lead sponsor
Berkovich, Regina MD, PhD Inc.
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Sep 9, 2026, 1:51 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis

NCT04925557
View directory record Official record
Conditions
Secondary-progressive Multiple Sclerosis
Interventions
Mayzent, Ocrevus
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 9, 2026, 1:51 AM EDT
Completed No phase listed Observational

A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients

NCT07566988
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 9, 2026, 1:51 AM EDT
Completed Not applicable Interventional

Proximal Resistance Training for People With Multiple Sclerosis

NCT04548154
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Proximal Resistance Training
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 64 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Sep 9, 2026, 1:51 AM EDT
Completed No phase listed Observational

Functional Intermuscular Reduction of Spasticity

NCT04403594
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
dry needling
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 9, 2026, 1:51 AM EDT
Completed Not applicable Interventional

Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis

NCT01848327
View directory record Official record
Conditions
Relapsing Remitting MS, Secondary Progressive MS, Primary Progressive MS
Interventions
Caprylic Triglyceride, Placebo
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 59 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Sep 9, 2026, 1:51 AM EDT
Recruiting No phase listed Observational

Ocrevus Zunovo for MS: Mixed Methods

NCT07710105
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Clinical Questionnaires, Semi-Structured Interviews, Ocrevus Zunovo
Other · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 9, 2026, 1:51 AM EDT
Active, not recruiting Phase 2 Interventional

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

NCT03712202
View directory record Official record
Conditions
Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Ann Arbor Stage I Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Mixed Cellularity Classic HL, Ann Arbor Stage II Nodular Sclerosis Classic HL
Interventions
Bleomycin, Brentuximab Vedotin, Dacarbazine, Doxorubicin, Nivolumab, Quality-of-Life Assessment, Vinblastine
Drug · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
16 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
17
States / cities
Birmingham, Alabama • Duarte, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Sep 9, 2026, 1:51 AM EDT
Recruiting Not applicable Interventional

This Clinical Trial Compares Two Phacoemulsification Systems Used in a Bilateral Cataract Surgery Subjects in Order to Study CDE and Ultrasound Time During Cataract Removal

NCT07468877
View directory record Official record
Conditions
Nuclear Sclerosis of the Lens, Phacoemulsification Cataract Surgery, Cataract Bilateral
Interventions
Cataract extraction with phacoemulsification comparing two systems
Device
Lead sponsor
Nicole Fram M.D.
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 9, 2026, 1:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating the Need for the Pseudophakic Intraoperative Abberrometry in Toric IOL Implantation

NCT03819842
View directory record Official record
Conditions
Cataract, Nuclear Sclerosis, Cortical Cataract, Posterior Subcapsular Cataract, Astigmatism
Interventions
Pseudophakic Measurement
Diagnostic Test
Lead sponsor
Alterman, Modi, & Wolter Ophthalmic Physicians & Surgeons
Other
Eligibility
30 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Poughkeepsie, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Sep 9, 2026, 1:51 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Macromolecular Imaging of White and Gray Matter Pathology in Multiple Sclerosis

NCT04415372
View directory record Official record
Conditions
Multiple Sclerosis, MS
Interventions
MRI, Neuropsychological Testing
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 9, 2026, 1:51 AM EDT
Completed Phase 1Phase 2 Interventional

Aerobic Exercise for Remyelination in Multiple Sclerosis

NCT04539002
View directory record Official record
Conditions
Multiple Sclerosis, Sclerosis, Demyelinating Diseases, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Demyelinating Autoimmune Diseases, CNS, Exercise
Interventions
Aerobic exercise, Education Group Control
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 9, 2026, 1:51 AM EDT
Completed Phase 3 Interventional Results available

Effects of Acthar on Recovery From Cognitive Relapses in MS

NCT02290444
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Adrenocorticotropic Hormone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2020 · Synced Sep 9, 2026, 1:51 AM EDT